• TechCrunch
• CrunchBase
• More
  • TechCrunch UK
  • TechCrunch France
  • TechCrunch Japan

Anaphore

edit

Anaphore (formerly ImmunoNewCo) is developing a new class of protein therapeutics to address significant unmet medical needs for patients with serious or life-threatening diseases.

Milestones

edit

• 
  Anaphore added Casey Logan as Senior Vice President, Business Development.
  Posted 6/20/11 at 6:18pm
• 
  Anaphore added Paul A. Grayson as President and CEO.
  Posted 6/20/11 at 6:18pm
• 
  Anaphore added Russell G. Greig as Chairman.
  Posted 6/20/11 at 6:18pm
• 
  Anaphore added Anke Kretz-Rommel as Vice President Research & Development.
  Posted 6/8/09 at 1:14am
• 
  Anaphore added Bruce D. Steel as Chief Business Officer.
  Posted 6/8/09 at 1:14am
• 
  Anaphore added Katherine S. Bowdish as CEO.
  Posted 6/8/09 at 1:14am
• 
  Anaphore received $3.3M in Unattributed funding. (1/31/08)
  Posted 9/17/09 at 7:38am via venturebeat.com
• 
  Anaphore received $13M in Series A funding. (6/9/09)
  Posted 6/16/09 at 10:25am via onbiovc.com
• 
  Anaphore received $8M in Unattributed funding. (4/15/08)
  Posted 6/8/09 at 1:14am via anaphoreinc.com

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/8/09

Sources

1. 5AM Ventures puts $3.3M into stealthy immunology startup ImmunoNewco (deals.venturebeat.com) [edit]
2. April 15, 2008 - Anaphore Receives $8M In Financing (anaphoreinc.com) [edit]
3. Anaphore, Inc.: Series A $13M (onbiovc.com) [edit]